Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.
| Revenue (Most Recent Fiscal Year) | $23.68M |
| Net Income (Most Recent Fiscal Year) | $-318.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 20.90 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.25 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -757.52% |
| Net Margin (Trailing 12 Months) | -757.53% |
| Return on Equity (Trailing 12 Months) | -101.60% |
| Return on Assets (Trailing 12 Months) | -58.41% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.80 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.75 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.53 |
| Inventory Turnover (Trailing 12 Months) | 1.36 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.50 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.98 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.72 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.86 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 86.05M |
| Free Float | 82.52M |
| Market Capitalization | $913.82M |
| Average Volume (Last 20 Days) | 3.07M |
| Beta (Past 60 Months) | 0.82 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.10% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |